101 Biomedical Prevention of HIV/AIDS in Russia
E. V. Karamov, R. M. Khaitov
National Research Centre Institute of Immunology, FMBA of Russia
102 HIV/AIDS Vaccines in Russia: Clinical Trials and Estimation of Acceptance in Population
G. O. Gudima
National Research Centre Institute of Immunology, FMBA of Russia
103 Genetic Factors Defining Resistance and Susceptibility to HIV/AIDS
I. A. Kofiadi
National Research Centre Institute of Immunology, FMBA of Russia
104 Cell-to-cell Transmission of HIV-1: Role of Virological Synapse
A. V. Filatov, D. V. Mazurov
National Research Centre Institute of Immunology, FMBA of Russia
105 Rationale for HIV/AIDS Vaccines Design
I. A. Nikolaeva
National Research Centre Institute of Immunology, FMBA of Russia
106 Enhance Expression of Transgene in Adenovirus
R. I. Ataullakhanov
National Research Centre Institute of Immunology, FMBA of Russia
107 The Modern Methods of HIV/AIDS Vaccine Evaluation
S. V. Korobova
National Research Centre Institute of Immunology, FMBA of Russia
108 Development of Universal Vaccines against Flu
M. M. Shmarov
Gamaleya Scientific Research Institute of Epidemiology and Microbiology of the Health Ministry of the Russian Federation (Russia)
109 Genetically Engineered Tuberculosis Subunit Vaccine
A. V. Tkachuk
Gamaleya Scientific Research Institute of Epidemiology and Microbiology of the Health Ministry of the Russian Federation (Russia)
110 Broadly Neutralizing Antibodies for Serotherapy and Vaccine Design
Antonio Lanzavecchia, MD
Director of the Institute for Research in Biomedicine (Switzerland)
111 Update on Dengue Vaccines
Alexander Schmidt, MD
Director, Clinical Research and Translational Science, GlaxoSmithKline Biologicals (US)
112 Development of Enterovirus 71 Vaccine
Li Xiuling*
National Vaccine and Serum Institute (China)
113 Epidemics of Acute Gastroenteritis Caused by Viruses and Vaccine Development in China
Shen Shuo, PhD*
Wuhan Institute of Biological Product (China)
114 Virus-Like Particles and Particle Vaccines
Luigi Buonaguro, MD*
Ist. Naz.Tumori “Fond. G. Pascale” (Italy)
115 Novel HIV Vaccine Strategies
Dan Barouch, MD, PhD
Director of the Centre for Virology and Vaccine Research in the Department of Medicine at Beth Israel Deaconess Medical Center (US)
116 Strategies and Mechanisms for Induction of Mucosal T Cell Immunity
Jay A. Berzofsky, MD, PhD
Chief, Vaccine Branch, Center for Cancer Research, National Cancer Institute (US)
117 30 Years of HIV Vaccine Research
José Esparza, MD, PhD
Senior Advisor on HIV Vaccines of the Bill and Melinda Gates Foundation (US)
118 The Dense Glycan Shield on the HIV Envelope: the Achilles Heel of the Virus?
Jan Balzarini, MD, PhD
Laboratory of Virology and Chemotherapy, Rega Institute (Belgium)
119 The Anti-HIV Drug Pipeline
John G. Bartlett, MD
Director, HIV Care Program, The Johns Hopkins Hospital (US)
120 Development of New HIV Inhibitors
S.N.Kochetkov
Laboratory of Enzymology of Transcription, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
121 Progress, Achievements and Challenges: a Review of China’s Free Antiretroviral Therapy Program
Fujie Zhang, MD*
National Centre for AIDS/STD Control and Prevention (China)
122 Peptide Inhibitors of HIV
Anders Vahlne, MD*
Karolinska Institute (Sweden)
123 New Antiretroviral Therapies
James Rooney, MD
Vice President of Medical Affairs, Gilead Sciences, Inc. (US)
124 HIV Transmission and Pathogenesis in ex vivo Tissues
Leonid Margolis, PhD*
Head, Section of Intercellular Interactions, Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
125 Progress toward a HIV cure
Alain Lafeuillade, MD*
Department of Infectious Diseases, Toulon General Hospital (France)
126 Questions and challenges in HIV drug resistance: A molecular perspective
Luis Menéndez-Arias, PhD*
Centro de Biologia Molecular “Severo Ochoa” (CSIC-UAM), Madrid (Spain)
127 Safety, pharmokinetics and efficacy of VM-1500, a novel reverse transcriptase inhibitor, In healthy volunteers and HIV-infected patients
Vadim Bichko, M.D.
Viriom Ltd. (Russia)
128 Cure of HBV infection: can APOBEC3 deaminases mediate it?
Ulrike Protzer, MD*
Institute of Virology, TU Munich (Germany)
129 Polio Vaccines: The Past, Present and the Future
Konstantin Chumakov, PhD*
Chief of the Laboratory of Method Development, Division of Viral Products in the Food and Drug Administration (US)
130 HTLV-I and Adult T Cell Leukemia/Lymphoma (ATLL): Cellular and Molecular Basis of Transformation
William Hall, MD
University College, Dublin (Ireland)
131 Replication and Assembly of Filoviruses
Stephan Becker, PhD*
Institute of Virology at the University of Marburg (Frankfurt, Germany)
132 A Novel Pathway of Proviral HIV-1 Latency Regulated by Aminoacid Starvation and HDAC-4
Guide Poli, MD*
Head, AIDS Immunopathogenesis Unit, San Raffaele Scientific Institute (Italy)
133 Ebola virus matrix: structural transformation begets multiple structures in the virus life cycle
Erica Ollmann Saphire, PhD*
Department of Immunology and Microbial Science of the Scripps Research Institute (US)
134 Host Restriction of Schmallenberg Virus
Massimo Palmarini, DVM, Ph.D., FRSE*
Chair of Virology, University of Glasgow Centre for Virus Research (UK)
135 HIV-associated immunodeficiency despite potent antiretroviral therapy with CD4 T cell reconstitution
C. David Pauza, PhD*
Institute of Human Virology, University of Maryland School of Medicine (US)
136 HIV-1 Nef regulates activity of endoplasmic reticulum chaperone calnexin
Michael Bukrinsky, MD, PhD
Department of Microbiology, Immunology and Tropical Medicine at the George, Washington University (US)
137 Interplay Between Host Defenses and Viral Anti-defenses: A Major Factor of Cytopathogenicity of Picornaviruses
V.I.Agol, MD, PhD, DSc
M.P.Chumakov Institute of Poliomyelitis and Viral Encephalitis, Russian Academy of Medical Sciences (Russia)
138 Understanding protective immunity: Lessons from measles
Diane Griffin MD, PhD*
Alfred and Jill Sommer Professor, Chair of the Department of Molecular Microbiology and Immunology, the Johns Hopkins Bloomberg School of Public Health (US)
139 Dengue Vector Control: Critical Needs and Opportunities for Helping to Control the Dengue Pandemic
Barry J. Beaty, PhD*
University Distinguished Professor, Department of Microbiology, Immunology and Pathology, Colorado State University (US)
140 Reversing the Epidemic of HIV-1C in Southern Africa with Treatment as Prevention
Myron Essex, DVM, PhD
Mary Woodard Lasker Professor of Health Sciences Harvard School of Public Health, Harvard University (US)
141 Gene Discovery and Data Sharing in Genome Wide Association Analyses: lessons from AIDS genetic restriction genes
Steven O’Brien
St. Petersburg State University (Russia)
142 Sochi Virus as a Highly Pathogenic and Life-threatening Agent
E.A.Tkachenko, MD, PhD, DSc
M.P. Chumakov Institute of Poliomyelitis and Viral Encephalitis, Russian Academy of Medical Sciences (Russia)
143 Rift Valley Fever Virus: a Virus with Potential for Global Emergence
Janusz T. Paweska, DVSc, dr hab., Prof Vet. Sci.*
Head, Centre for Emerging and Zoonotic Diseases, National Institute for Communicable Diseases National Health Laboratory Service (South African Republic)
144 Viral-Bacterial Mixed Infections Transmitted by Ticks: Diagnosis and Prevention in Russia
E. I. Korenberg
Gamaleya Scientific Research Institute of Epidemiology and Microbiology of the Health Ministry of the Russian Federation
145 Arbovirus and Related Infectious Diseases in China
Guodong Liang, MD*
National Institute for Viral disease Control and Prevention, China CDC (China)
146 Understanding the Pathogenesis of Prion and Surveillance for Human Prion Diseases in China
Xiaoping Dong, PhD*
National Institute for Viral Disease Control and Prevention, China CDC (China)
147 Globalization and New Challenges Caused of Communicable Diseases
Saulius Chaplinskas, MD, PhD
Director, Center for Communicable Diseases and AIDS (Vilnus, Lithuania)
148 HPV, HIV, and Cancer: A Global Challenge
Silvia Franceschi, MD
Special Advisor, Head, Infections and Cancer Epidemiology Group, International Agency for Research on Cancer (IARC) (Lyon, France)
149 HCV and Lymphoma
Anna Linda Zignego, MD, PhD
Director, Interdepartmental Center MaSVE, Department of Experimental and Clinical Medicine, University of Florence (Italy)
150 Carcinogenesis of HPV
Franco M. Buonaguro, MD*
Director, Molecular Biology and Viral Oncogenesis Unit, National Cancer Institute “Fondazione G. Pascale” (Naples. Italy)
151 Tumorigenic Polyoma Viruses
Patrick Moore, MD, MPH*
Professor, Department of Microbiology and Molecular Genetics, School of Medicine and Department of Infectious Diseases and Microbiology, University of Pittsburgh (US)
152 Insights into the pathogenesis of HHV8-driven body cavity lymphomas
Luigi Chieco-Bianchi, MD*
Immunology and Molecular Oncology, Veneto Institute of Oncology, Dept of Surgery, Oncology & Gastroenterology, University of Padua (Italy)
153 Molecular Pathogenesis by HTLV-1 bZIP Factor
Masao Matsuoka, MD, PhD
Institute for Virus Research, Kyoto University (Japan)
154 HIV and Cancer in Africa
William A. Blattner, MD*
Professor and Associate Director, Institute of Human Virology, University of Maryland School of Medicine (US)
155 Evolution by Tumor Neofunctionalization and Phenomenon of Tumor Specifically Expressed, Evolutionarily Novel (TSEEN) Genes
A. P. Kozlov
Professor and Director, Biomedical Center (St. Petersburg, Russia)
156 HIV and metabolic disease: Clues to control of HIV infection from the immune and viro logical response to high dose Vitamin D challenge
Barry Peters, MBBS, DFFP, MD, FRCP
King’s College London (UK)
157 Pathogenesis of Epstein-Barr Virus-driven Lymphomas of HIV+ Patients: new insights of potential clinical relevance
Riccardo Dolcetti, MD*
Head, Cancer Bio-Immunotherapy Unit, IRCCS—National Cancer Institute (Italy)
158 Hepatitis C Treatment Update: Current Status and Future Directions
Shyam Kottilil, MD, PhD
National Institute of Allergy and Infectious Diseases (US)
159 Hepatitis B Treatment Update: Current Status and Future Directions
Rohit Talwani, MD*
Institute of Human Virology, University of Maryland School of Medicine (US)
160 Treatment Strategies to Minimize the Impact of Antiretroviral Drug Toxicities
Bruce Gilliam, MD*
Institute of Human Virology, University of Maryland School of Medicine (US)
161 Anti-tuberculosis Treatment for HIV-positive Patients in Moscow
E.M.Bogorodskaya, MD, PhD
Moscow City Research and Practical Centre for Tuberculosis Control (Russia)
162 Confronting Tuberculosis in an African Population with HIV
Abubakar Mussa Maghimbi, MD, MMed
Institute of Human Virology (Dar es Salaam, Tanzania)
163 HIV and kidney function with a focus on traditional risk factors and role of TDF, PI and other medication
Patrick Mallon, MD, PhD
Associate Dean for Research and Innovation, UCD School of Medicine and Medical Science (Ireland)
*Abstracts appear as provided by authors
Footnotes
GVN Member
